Table 8.

Impact of prostate artery embolization on the ejaculatory status.

Reference	Aim	Study Design	Main Results	EjD Results
Amouyal et al., Cardiovasc Intervent Radiol. Mar 2016 [49]	To report experience and clinical results on patients suffering from symptomatic BPH, who underwent PAE aiming at using the PErFecTED technique.	Single-center retrospective open label N 32	Mean IPSS decreased from 15.3 to 4.2 (p = 0.03), mean QoL from 5.4 to 2 (p = 0.03), mean Qmax increased from 9.2 to 19.2 (p = 0.25)	No retrograde ejaculation
Salem et al., Urology 2018 [51]	To evaluate the safety and efficacy of prostate artery embolization (PAE) for lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia	Prospective, single-center, open-label N 45	At 1 month, improvements in IPSS (23.6 ± 6.1 to 12.0 ± 5.9, p < 0.0001), QoL (4.8 ± 0.9 to 2.6 ± 1.6, p < 0.0001), Qmax (5.8 ± 1.0 to 12.4 ± 6.8, p < 0.0001). At 3 months, there were improvements in IPSS (10.2 ± 6.0, p < 0.0001), QoL (2.4 ± 1.6, p < 0.0001) and Qmax (15.3 ± 12.3, p < 0.0001). At 6 months, there were improvements in IPSS (11.0 ± 7.6, p < 0.0001) and QoL (2.3 ± 1.7, p < 0.0001). At 1 year, there were improvements in IPSS (12.4 ± 8.4, p < 0.0001) and QoL (2.6 ± 1.6, p < 0.0001).	No adverse effects on erectile function or sexual health
Ray et al., BJU Int. August 2018 [52]	To assess the efficacy and safety of prostate artery embolization (PAE) for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and to conduct an indirect comparison of PAE with transurethral resection of the prostate (TURP)	Multicenter N 305	Median 10-point IPSS improvement from baseline at 12 months post-procedure	24.1% retrograde ejaculation rate for EAP against 47.5% for RTUP